Zami Aberman

President & CEO

Mr. Aberman joined Pluristem in September 2005 and changed the Company’s strategy towards cellular therapeutics. Mr. Aberman has 20 years of experience in marketing and management in the high technology industry. He has held Chief Executive and Chairman positions in Israel, the USA, Europe, Japan and Korea. He has operated within high-tech global companies in the fields of automatic optical inspection, network security, video over IP, software, chip design and robotics. Continued... on copr-website.

Yaky Yanay,

VP Finance & CFO

Prior to joining Pluristem, Mr. Yanay was the Chief Financial Officer of Elbit Vision System Ltd. (EVSNF.OB), a company engaged in automatic optical inspection. He has extensive experience in the financing and management of technology companies. He played a major role in planning and executing a turn-around plan for Elbit Vision System, including the completion of three acquisitions and the raising of more than $20 million, resulting in a tripling of the company’s revenues and attaining profitability. Mr. Yanay began his financial career at Ernst &Young Israel in 1999, where he served as a manager of audit groups for the technology sector. He joined Ernst &Young’s financial team after serving in the Israeli Ministry of Foreign Affairs since 1993.

Mr. Yanay holds a bachelor’s degree with honor in business administration and accounting from the College of Management Studies in Rishon Le Zion, Israel and is a Certified Public Accountant in Israel.

William R. Prather RPh, MD,

Senior VP Corporate Development

William R. Prather RPh, MD, is a Registered Pharmacist as well as a Board Certified Internist and Geriatrician. Dr. Prather received his BS in Pharmacy (1970) and medical degree (1973) from the University of Missouri. He practiced internal medicine in the Kansas City, MO and Vail, CO areas until leaving Internal Medicine in 1987 to pursue a Fellowship in Geriatric Medicine at Harvard University. He completed this Fellowship in 1989.

In 1992 Dr. Prather left the practice of medicine to pursue a career in the financial industry where he has held Senior Healthcare research positions for a variety of investment banks . Dr. Prather co-founded Panacos, Inc. (NASDAQ:PANC), a public pharmaceutical company. Additionally, he has been on the Boards of several public and private companies, including Boston Biomedica Inc. (a public medical diagnostics company), PriMed (a private medical device company), MdBio (a Maryland healthcare venture firm), and sat on the Advisory Board of MDS Capital Management, (a Canadian venture firm).

Frank C. Carlucci

Business Strategy Advisory Board

Mr. Carlucci has been a Managing Director of Carlyle since 1989, Chairman since 1993 and Chairman Emeritus since January 2003. Mr. Carlucci was Secretary of Defense from November 1987 through January 1989, following his service as Assistant to the President for National Security Affairs under President Reagan. Before serving in these positions, Mr. Carlucci was Chairman and CEO of Sears World Trade, a business he joined in 1983. Mr. Carlucci preceded his affiliation with Sears World Trade, Inc. with a career in government service, which included Deputy Secretary of Defense (1980-82), Deputy Director of Central Intelligence (1978-80), Ambassador to Portugal (1975-78), Under Secretary of Health Education and Welfare (1973-75), Deputy Director of OMB (1970-72), and Director of the Office of Economic Opportunity (1969). Mr. Carlucci was a Foreign Service Officer from 1956 to 1980 and he served as an officer in the U.S. Navy from 1952 to 1954.

Mr. Carlucci is Chairman Emeritus of Nortel Networks and the US-Taiwan Business Council and the Chairman of the Neurogen Corporation Board of Directors. Additionally, Mr. Carlucci serves as a member on the following corporate boards: SunResorts, Ltd., N.V.; Texas Biotechnology Corporation and United Defense L.P.

Philip S. Schein, M.D

Business Strategy Advisory Board

Dr. Philip Schein is widely regarded as a leading international authority in the treatment of cancer. He currently serves as a Visiting Professor in Cancer Pharmacology, Oxford University, and President of The Schein Group, which provides consultative services to the pharmaceutical industry. He is a former President of the American Society of Clinical Oncology, Chairman of the FDA Oncology Drugs Advisory Committee and a member of the National Cancer Advisory Board. His prior appointments were at the National Cancer Institute, Bethesda, Maryland where he served as Senior Investigator and Head of the Clinical Pharmacology Section of the Medicine Branch and at Georgetown University School of Medicine in Washington, DC, as Professor of Medicine and Pharmacology and Scientific Director of the Vincent T. Lombardi Cancer Research Center. He has also served as Vice President of Worldwide Clinical Research and Development, and Director of the Laboratory of Molecular Oncology, SmithKline & French Laboratories, where he had responsibility for all SK&F clinical research and development activities. In 1987 he founded US Bioscience, a pharmaceutical company focused in the field of oncology, where he served as Chairman and CEO of U.S. Bioscience and took three products, Ethyol, Neutrexin and Hexalen, through development and regulatory approval in the US, Europe, Canada and other countries.